Key Takeaways
- Acquisition defines the quarter: Ipca is acquiring a 33.38% stake in Unichem Laboratories, triggering an open offer for another 26%, a deal management calls better than most seen in five years.
- Bold EBITDA target, synergy-dependent: Management expects Unichem to reach ₹300 crores EBITDA on ~₹1,800 crores turnover within two years of taking control, a target that explicitly includes synergy benefits and would be a challenge without them.
- Unichem is underutilized, not broken: Capacity utilization sits at just 20–30% across plants, and API batch-size/yield issues are dragging margins, but the quality and operations team is seen as competent and the order book is strengthening.
- US FDA overhang persists for both: Ipca’s own facilities remain in status quo with no inspection scheduled, while Unichem’s last US FDA inspection was in 2020; management can offer only hope, not a timeline.
- What to watch next quarter: Progress on CCA approval and the open offer timeline, any US FDA inspection notice for Ipca’s Ratlam facility, and early signs of the API cost-optimization program at Unichem.
The Unichem Acquisition: Rationale, Structure & Synergies
- Deal structure: Ipca signed an SPA to acquire 33.38% of Unichem from the Dr. Modi family, triggering a mandatory open offer for an additional 26%; management control passes to Ipca upon deal completion irrespective of the final shareholding percentage.
- Financing: The acquisition is funded entirely through internal accruals; borrowing from banks is not permitted for share purchases, while working capital will use working capital finances. No shareholder approval is required from Ipca’s side.
- No merger, no full buyout: Unichem will remain a listed entity with public holding above 25%; there is no plan to merge Unichem with Ipca or to acquire 100% of the company, though the preferential route to increase stake remains open.
- Synergy logic: Ipca can extend Unichem’s already-developed US generics into Australia, New Zealand, and Europe where Ipca already has a presence, while also marketing Unichem’s branded formulations in RoW markets. Site transfers are possible in both directions.
- Backward integration opportunity: Most of Unichem’s APIs come from its own backward integration site but from late-stage intermediates; Ipca can add value by supplying more cost-efficient intermediates, especially once its Ratlam facility secures US approval.
- No cash infusion required: Scaling Unichem to ₹1,800 crores does not need any cash infusion from Ipca; unlocking the ~₹275 crores GST refund stuck due to a method choice and rationalizing the supply chain will release sufficient cash.
Pranay Godha: "It was better than most of the deals that had come on our table in the last five years."
Unichem’s Current State: Assets, Utilization & Inefficiencies
- Portfolio depth: Unichem has around 75 ANDAs filed, 54 approved, and about 40 currently marketing, with another 10–12 products to be launched over time; most are me-too generics, with nothing first-to-file.
- Facility footprint: Unichem operates three API plants and three formulation plants, of which two formulation and three API plants are US FDA approved; a newly commercialized Goa facility is more automated with recipe-based operations and minimal human intervention.
- Severe underutilization: Pithampur and Piparia plants are running at only 25–30% utilization; Unichem’s overall capacity utilization may be around 20–30%, leaving significant headroom for growth without major capex.
- Margin compression is mix-driven: Nine-month gross margins fell to ~59% from an annual run rate of 66–67% because of product mix; on a normalized basis, management expects gross margins of 60–65%.
- Two core inefficiencies: Low capacity utilization and API batch-size/yield problems are the basic issues plaguing Unichem; management did not elaborate on the root causes of those inefficiencies when pressed.
- CMO strength: Unichem has strong credibility with key European clients on the CMO side, with a track record that has historically been difficult for competitors to match on certain projects.
- Non-US business mix: Beyond the US, Unichem’s business spans CMO (primarily European customers), Brazil formulations, UK business, and API sales dominant in Europe and emerging markets; emerging markets are more profitable on a percentage basis, while CMO and Brazil are becoming more profitable in absolute terms.
Ajit Jain: "Nobody can ever guarantee what will happen in the future. There is no guarantee of what FDA can do in the future for anyone, for any site on this world."
The ₹300 Crore EBITDA Target: Drivers & Conditions
- The target: Management expects Unichem to achieve ~₹300 crores EBITDA on ~₹1,800 crores turnover in the second year after Ipca takes management control, up from a current revenue base of roughly ₹1,250 crores.
- Three drivers: Sales growth from an improving order book, operational efficiency improvement in API facilities, and synergy benefits from Ipca’s market reach and backward integration capabilities.
- Synergy-dependence is explicit: Pranay Godha stated the ₹300 crores EBITDA target includes synergy benefits and that without them, the number would be a challenge; the target is not a baseline forecast but an ambition requiring successful integration.
- API cost optimization is the critical workstream: The key API cost-optimization program can be planned and implemented in around one and a half years, though it could take longer because API changes require device process validation and formulation batch testing.
- R&D rationalization: Ipca’s policy is to develop products only on its own API, not third-party API; applying this to Unichem is expected to generate significant R&D savings.
- Overhead optimization: Once Ipca takes management control, it will review Unichem’s entire overhead structure; gross margins are not seen as an issue and can be further enhanced through process optimizations and cost reductions, particularly on the API side.
- Peak potential beyond the target: Management estimates Unichem’s assets can generate peak potential revenue of around ₹2,700–2,800 crores, well above the two-year target, though no timeline is attached to that figure.
Pranay Godha: "It does include synergy benefits. Without that, this number would otherwise be a bit of a challenge."
US Market & Regulatory Overhang
- Ipca’s FDA status: Status quo with no development; management can only express hope that an inspection will happen soon, with no visibility on timing.
- Unichem’s FDA status: The last inspection among Unichem’s five approved sites was in 2020, pre-COVID; no CGMP inspection is currently scheduled for any Unichem facility, though all facilities are inspected by every regulator of the world and have all the approvals.
- Ratlam optimism: Management is optimistic that Ipca’s Ratlam facility will have a positive outcome in the very near future; with that assumption, Ipca can become a primary supplier of raw materials and APIs for Unichem’s core products, unlocking the backward integration synergy.
- US market rationale: Management views the US as a market Ipca must re-enter as fast as possible, calling it the largest generic market suited to the kind of products both Ipca and Unichem are involved in; prices are seen as becoming more rational and stabilized, creating opportunity for compliant, competitive companies.
- Margin structure reality: In the US generics market, there is very little space for multiple margin layers through the value chain; companies with multiple intermediaries cannot remain competitive year on year, which is why backward integration matters.
Ajit Jain: "Nothing, there is status quo. So let us hope, inspection will happen soon and we are through. But as we speak, there is status quo. No development."
Integration Approach & Management Philosophy
- Business as usual at Unichem: No significant management changes are planned; the quality and operations team has done a good job and their actions are seen as speaking louder than words. Ipca’s interventions will be larger on the API front to build operating efficiencies.
- Quality systems: No major changes expected to Unichem’s quality systems as of now; systems will be updated as per CGMP requirements when needed, consistent with the proactive approach any company in the space must maintain.
- ESOP continuity: Unichem’s existing ESOP scheme cannot be changed to the detriment of grantees once passed by shareholders and is generally valid for ten years.
- European Commission fine: The matter is yet to be finally settled and remains in court; it was already considered while calculating the deal, and several possibilities and options exist.
- Jogeshwari land: Unichem holds ~10.5 acres of land in Jogeshwari with the possibility to monetize over time, though no timeline or valuation was provided.
- Pithampur API plant: The plant carries ~₹100 crores of CWIP and will need rework using chemical engineering methods to improve throughput.
Management: "Whatever the team, in the quality and operation side, they've generally done a good job. Their actions are speaking louder than words, I would say. So, things will more or less, be business as usual."
Unanswered Questions & Pushback
- Valuation benchmarks: When asked what valuation benchmarks or multiples were used to justify the acquisition price, management pointed to the ₹1,800 crores / ₹300 crores EBITDA target but did not provide the multiples or methodology.
- Payback period: Management acknowledged known assets like the Jogeshwari land (~₹250–300 crores) and the GST refund but said payback calculations have not been done and it is difficult to say what the payback would be, as the scenario will change with market extensions.
- ROCE/ROE potential: When pressed on whether Unichem assets could achieve 20%+ ROCE/ROE similar to Ipca’s past performance, management declined to comment, saying it depends on integrations and market extensions.
- Other bidders: Management stated they are not aware of any other deal the sellers were discussing or any other bidders in the process.
- Root causes of inefficiency: When asked what is plaguing Unichem’s broader business, management cited capacity utilization and API batch-size/yield issues but did not explain the underlying root causes.
- Per-ANDA cost concern: An analyst asked management to rethink the valuation given investor concerns about the high per-ANDA cost implied by the deal; management did not directly address the rethink request.
Ajit Jain: "We have talked about a lot of things which Ipca will do with their product range in terms of extending the market reach of those products. And right now, we have not made any of those kind of calculations. So right now, it's difficult to say that what would be the payback."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Unichem revenue target | ~₹1,700–1,800 crores turnover | Within two years of Ipca taking management control |
| Unichem EBITDA target | ~₹300 crores EBITDA, including synergy benefits | Second year after Ipca takes management control |
| Unichem gross margin normalization | 60–65% on a normalized basis | No specific timeline; dependent on product mix normalization |
| API cost optimization program | Planned and implemented across Unichem’s API operations | Approximately one and a half years, possibly longer due to validation requirements |
| Deal completion | CCA approval followed by open offer completion | Best case approximately four months from now, dependent on CCA approval timing |
| GST refund unlocking | Switch from refund method to rebate method to release ~₹275 crores | Maybe over a period of one year |
| R&D rationalization at Unichem | Shift to Ipca’s policy of developing products only on own API | Post-acquisition, no specific completion date |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Acquisition stake in Unichem Laboratories | 33.38% for INR1,034 cr |
| Open offer for additional stake | 26% of Unichem equity, aggregating to INR806 cr presuming 100% response |
| Total potential investment | INR1,839.5 cr if 100% of open offer shares are available |
| Unichem US ANDAs filed | 76 ANDAs filed, 54 registered, 44 products marketed |
| Unichem API DMFs filed in US | 78 DMFs |
| Unichem total assets on books | ~INR1,400 cr |
| Unichem net working capital | ~INR950 cr |
| Unichem total available assets | ~INR2,500–2,600 cr |
| Unichem capacity utilization | 20% to 30% currently |
| Ipca Pithampur plant utilization | ~30% |
| Ipca Piparia plant utilization | ~25% to 30% |
| Unichem revenue guidance (2 years out) | ~INR1,700–1,800 cr |
| Unichem EBITDA guidance (2 years out) | ~INR300 cr, including synergy benefits |
| Unichem revenue growth expectation | 15% to 17% in next 2–3 years |
| Unichem US revenue contribution | 60%–65% of total business |
| Unichem top 10 products contribution | 70%–75% of total business |
| Unichem normalized gross margin expectation | 60% to 65% |
| Unichem GST refunds locked up | ~INR275 cr, unlockable over ~1 year |
| Unichem peak potential revenue from all assets | ~INR2,700–2,800 cr |
| European Commission fine on Unichem (contingent liability) | INR120 cr, already considered in acquisition valuation |
| Deal timeline (best case) | ~4 months from now, subject to CCA approval |